INSMED Inc. Files 8-K Report
Ticker: INSM · Form: 8-K · Filed: 2024-03-11T00:00:00.000Z
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
INSMED filed an 8-K on March 8th for 'Other Events' - details TBD.
AI Summary
On March 8, 2024, INSMED Inc. filed an 8-K report to disclose "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the report filing date.
Why It Matters
This filing indicates that INSMED Inc. has reported significant events to the SEC, which could impact investors' understanding of the company's current status.
Risk Assessment
Risk Level: medium — The lack of specific details in the 8-K filing creates uncertainty, requiring further investigation to assess the actual risk.
Key Numbers
- 000-30739 — Commission File Number (Identifies the specific SEC filing for INSMED Inc.)
- 54-1972729 — IRS Employer Identification No. (Tax identification number for INSMED Inc.)
Key Players & Entities
- INSMED Inc. (company) — Registrant
- March 8, 2024 (date) — Date of earliest event reported
- Virginia (jurisdiction) — State of incorporation
- 700 US Highway 202/206 Bridgewater, New Jersey 08807 (address) — Principal executive offices
FAQ
What specific 'Other Events' are being reported by INSMED Inc. in this 8-K filing?
The provided text of the 8-K filing does not specify the nature of the 'Other Events'.
What is the significance of the filing date being March 8, 2024?
March 8, 2024, is the date of the earliest event reported in the 8-K filing.
Where are INSMED Inc.'s principal executive offices located?
INSMED Inc.'s principal executive offices are located at 700 US Highway 202/206 Bridgewater, New Jersey 08807.
What is the Commission File Number for INSMED Inc.?
The Commission File Number for INSMED Inc. is 000-30739.
Under which section of the Securities Exchange Act of 1934 is this 8-K report filed?
This 8-K report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Stats: 511 words · 2 min read · ~2 pages · Grade level 13.7 · Accepted 2024-03-11 09:27:59
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share INSM Nasdaq Global Select
Filing Documents
- ef20023812_8k.htm (8-K) — 24KB
- 0001140361-24-012513.txt ( ) — 155KB
- insm-20240308.xsd (EX-101.SCH) — 4KB
- insm-20240308_lab.xml (EX-101.LAB) — 21KB
- insm-20240308_pre.xml (EX-101.PRE) — 16KB
- ef20023812_8k_htm.xml (XML) — 4KB
01 – Other Events
ITEM 8.01 – Other Events. On March 8, 2024, Insmed Incorporated (the "Company") received notice of the exercise by AstraZeneca AB ("AstraZeneca") of its second and final option under the License Agreement, dated October 4, 2016, by and between the Company and AstraZeneca (the "License Agreement"), to further develop and, if approved, commercialize brensocatib in the indications of chronic obstructive pulmonary disease ("COPD") or asthma. The exercise of this second option will permit AstraZeneca to develop brensocatib beyond Phase 2b clinical trials and, if approved, commercialize brensocatib in the indications of COPD or asthma, upon reaching agreement after good faith negotiations resulting in terms, including financial terms, satisfactory to both the Company and AstraZeneca for such further development and commercialization. The Company and AstraZeneca each retain all discretion to determine, among other things, whether any proposed terms are acceptable to such party. The Company retains full development and commercialization rights for brensocatib in all other indications.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 11, 2024 INSMED INCORPORATED By: /s/ Michael A. Smith Name: Michael A. Smith Title: Chief Legal Officer and Corporate Secretary